Le Lézard
Classified in: Health
Subjects: CHI, HSP, AVO

Statement of Stacey D. Stewart, President and CEO, March of Dimes on the Administration Finalizing its "Public Charge" Rule Endangering Pregnant Women & Children


ARLINGTON, Va., Aug. 12, 2019 /PRNewswire/ -- March of Dimes released the following statement from Stacey D. Stewart, President and CEO, in response to the Administration's action today finalizing the rule on the circumstances under which immigrants could be considered a "public charge," thereby endangering their immigration status. March of Dimes submitted formal comments on the proposed rule in December last year raising its serious concerns.

March of Dimes Foundation Logo (PRNewsfoto/March of Dimes Foundation)

"March of Dimes is extremely concerned with Administration's action today finalizing the "public charge" rule, which goes against our nation's values. This misguided action will cause pregnant women and families to avoid the entirely legal and permissible use of Medicaid and the Supplemental Nutrition Assistance Program (SNAP), resulting in significant harm to their health. Women who do not have access to medical services run the risk of a vast range of health issues that have implications for their present and future wellbeing, as well as that of their child.

"The rule would put in place daunting disincentives that will leave millions of women, children and families without access to programs that address their basic health needs. In addition to driving eligible individuals away from Medicaid and SNAP, this will also cause an exodus from other critical programs. Public health will suffer not only from the direct morbidity and mortality caused by lack of access to care, but from the consequences of untreated infectious disease and other conditions. The result will be significant, unnecessary and potentially lifelong harm to the health and wellbeing of women, children and families.

"It is important to note that this policy does not actually change immigrants' eligibility for these programs. Rather, it punishes them for taking advantage of the services they need and for which they are eligible. We urge the Department of Homeland Security to immediately reverse course and withdraw this rule in its entirety and focus instead on building strong, healthy communities."

About March of Dimes

March of Dimes leads the fight for the health of all moms and babies. We support research, lead programs and provide education and advocacy so that every baby can have the best possible start. Building on a successful 80-year legacy of impact and innovation, we empower every mom and every family.

Visit marchofdimes.org or nacersano.org for more information. Visit shareyourstory.org for comfort and support. Find us on Facebook and follow us on Instagram and Twitter.

SOURCE March of Dimes


These press releases may also interest you

at 05:11
Hyundai Bioscience announced on April 25th that its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cancer caused by p53 gene mutations. Mutations in the p53 gene occur in almost...

at 04:31
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CHINA, HONG KONG, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR...

at 04:30
The Balance RehabClinic, renowned for its luxury mental health and addiction services, proudly announces its expansion into The Balance Healthcare Group: a collection of premium mental health solutions tailored for affluent individuals. These new...

at 03:47
Zest Dental Solutions, a global leader in innovative dental solutions proudly announces a strategic partnership with The Pathway. Founded by Justin Moody, DDS and based in Arizona, The Pathway is a continuing education program that teaches dentists...

at 03:34
Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease...

at 03:16
First quarter Net sales reached SEK 9.4 (13.0) million.The operating result totaled SEK -18.4 (-14.4) million.Earnings per share, basic and diluted, were SEK -0.11 (-0.09).Cash flow from operating activities totaled SEK -7.3 (-12.2) million.CEO...



News published on and distributed by: